Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for high-impact, difficult-to-treat cancers. Founded in 2015 and headquartered in Fort Worth, Texas, the company's mission is to provide patients with hard-to-treat cancers the opportunity to live longer and better by slowing, stopping, or shrinking tumors with minimal adverse effects.

The company's lead investigational drug is elraglusib (formerly 9-ING-41), a novel Glycogen Synthase Kinase-3 (GSK-3) inhibitor. Elraglusib targets multiple molecular pathways involved in tumor growth and resistance to conventional cancer treatments by inhibiting NF-κB and DNA Damage Response (DDR) pathways. It also mediates anti-tumor immunity through the regulation of immune checkpoints and immune cell function. Elraglusib is being developed in both injectable and oral tablet formulations for various oncology indications, including metastatic pancreatic cancer, refractory pediatric malignancies (such as Ewing sarcoma and neuroblastoma), and metastatic melanoma.

Actuate Therapeutics went public in August 2024, listing on Nasdaq under the ticker symbol ACTU. Recent notable developments include the selection of elraglusib for evaluation in the BEACON2 Trial for High-Risk Pediatric Neuroblastoma and the presentation of compelling clinical data for elraglusib in first-line metastatic pancreatic cancer at ASCO in June 2026. Additionally, the FDA cleared an Investigational New Drug (IND) application for an oral formulation of elraglusib in May 2026, advancing its development program. Daniel M. Schmitt serves as the CEO, President, and Director of the company.